Moderna’s positive trial results for a personalized melanoma vaccine triggered a massive Wall Street rally, offering the biotech company a dramatic second act after years of steep stock declines, cash burn and political headwinds. The targeted mRNA technology is designed to train the immune system to fight cancer, but regulatory and manufacturing hurdles remain before it can reach patients. The coverage also includes the real-estate boom transforming the Catskills and auto critic Dan Neil’s report from the Concours d’Lemons, where unusual, unpopular cars compete for “Worst in Show.”